Phase 2 N=5 LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Melanoma
Primary: Dose Limiting Toxicity (DLT) [Phase I] — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 S-Equol in Alzheimer's Disease 2 Trial
Alzheimer Disease
Primary: Cytochrome Oxidase/Citrate Synthase (COX/CS) Activity — -0.0000049; 0.0000195; 0.0000245 1/(seconds multiplied by micromoles) — p=>0.05
Phase 2 N=25 A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
NASH - Nonalcoholic Steatohepatitis
Primary: Safety and Tolerability of LPCN 1144 — 10 Participants
Phase 2 N=87 A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Leukemia, Lymphoid · Lymphoma, Non-Hodgkin · Lymphoma, Mantle-Cell
Primary: Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee — 71.4 Percentage of participants
Phase 2 N=32 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Phase 2 N=21 Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS) · Hematopoietic Stem Cell Transplant (HSCT)
Primary: Number of Non-relapsed Deaths by 100 Days Post-transplant in Pediatric Patients Receiving a Myeloablative or Reduced-intensity Preparative Regimen Prior to HSCT for…
Phase 2 N=5 Nitrous Oxide Analgesia Vaso-occlusive Crisis
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Pain Score — 5.7 score on a scale
Phase 2 N=12 Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
Prader-Willi Syndrome · Obesity
Primary: Microbiome Analysis: Alpha Diversity — 4.89 Shannon index
Phase 2 N=165 Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
Cigarette Smoking · Nicotine Dependence
Primary: 7-Day Point Prevalence Abstinence — 30; 44 Participants
Phase 2 N=248 Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 62.2; 65.1; 50.6 percentage of participants
Phase 2 N=30 Mirabegron and Physiological Function in Cold Environments
Resting Energy Expenditure · Thermogenesis · Brown Adipose Tissue
Primary: Cumulative Resting Energy Expenditure — 456.4; 494.7; 481.3; 492.8 kcal
Phase 2 N=38 A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants in Clinical Response at Week 12 — 53.8; 50.0 Percentage of participants
Phase 2 N=6 VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa
Status Epilepticus, Electrographic · Coma
Primary: Primary Pharmacologic Outcome - Absorption — 6; 0 Participants
Phase 2 N=512 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Infections, Respiratory · Virus Diseases · Infection Viral
Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each…
Phase 2 N=45 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
Hepatitis C Infection · HIV Infection
Primary: Percentage of Participants With Sustained Virologic Response at 12 Weeks Post Treatment Discontinuation (SVR12) — 84.4 percentage of participants